Vital

Dosing

Retatrutide Dosage Chart: Trial Doses and Unit Math

A retatrutide dosage chart built from published trial records, with the escalation steps each trial used, unit math with hypothetical numbers, and why no approved dose exists yet.

Last reviewed

The Vital angle

When you add a vial in Vital, you enter the mg in the vial and the liquid in mL, and the app shows the concentration, the U-100 units and mL to draw for the amount your prescriber or trial team gave you, and the doses per vial. It highlights a draw that is more than a 1 mL syringe holds. Each dose log keeps its unit, and reminders can repeat on set weekdays or every few days.

Retatrutide dosage chart: the short answer

There is no approved retatrutide dosage chart. Retatrutide is an investigational drug from Eli Lilly and Company. On November 20, 2026, the FDA had not approved it for any use, so no label, no approved dose, and no approved titration schedule exist. Every chart online that looks official copies one of the clinical trial designs, or it invents a new one.

What you can check is what the trials used. In the phase 2 obesity trial published in the New England Journal of Medicine, the highest arm started at 2 mg once weekly and went up to 4 mg, 8 mg, and then 12 mg. A second phase 2 trial, in people with chronic kidney disease, lists a different ladder: 2, 4, 6, 9, and 12 mg, with a step every 4 weeks. The tables below report those designs as trial facts. They are not a plan for you, and this guide does not give a dose.

Regulatory status first

Before you read any chart, know what retatrutide is and is not.

  • Investigational. Retatrutide is a GIP, GLP-1, and glucagon receptor agonist. It is still in clinical trials. ClinicalTrials.gov lists TRIUMPH-1, the main phase 3 obesity trial, as completed in 2026, but trial results are not an approval.
  • Not legal to compound. The FDA says retatrutide cannot be used in compounding under federal law. It is not a component of an FDA-approved drug.
  • "Research use only" products are not medicines. The FDA has sent warning letters to sellers of retatrutide labeled "for research purposes" or "not for human consumption." These products have no verified identity, purity, or strength.

If you are in a trial, the trial team gives your dose and your schedule. If someone outside a trial offers you retatrutide, ask your healthcare provider about it before you do anything else.

Phase 2 obesity trial: the doses and starting points

The phase 2 obesity trial (NCT04881760) enrolled 338 adults with obesity, or with overweight and at least one weight-related condition. It ran for 48 weeks. Each arm took one injection once weekly. The ClinicalTrials.gov record lists the arms like this:

Trial arm Start Steps listed in the trial record
1 mg 1 mg No escalation
4 mg, 2 mg start 2 mg 2 mg, then 4 mg
4 mg, 4 mg start 4 mg No escalation
8 mg, 2 mg start 2 mg 2 mg, then 4 mg, then 8 mg
8 mg, 4 mg start 4 mg 4 mg, then 8 mg
12 mg, 2 mg start 2 mg 2 mg, then 4 mg, then 8 mg, then 12 mg
Placebo none Placebo once weekly

The published results reported mean weight change at 48 weeks of -8.7% with 1 mg, -17.1% with the combined 4 mg groups, -22.8% with the combined 8 mg groups, and -24.2% with 12 mg, against -2.1% with placebo. The most common side effects were gastrointestinal. The authors reported that these were dose-related and were partly reduced with a lower starting dose, 2 mg against 4 mg.

That last finding is why so many charts start at 2 mg. It is a result from one trial population with medical supervision. It is not proof that any schedule is safe outside a trial.

A second trial: a five-step ladder

A later phase 2 trial of kidney function (NCT05936151) used different steps. Its ClinicalTrials.gov record describes them like this:

Trial weeks Weekly dose in the trial record
1 to 4 2 mg
5 to 8 4 mg
9 to 12 6 mg
13 to 16 9 mg
17 and later 12 mg target

The record says participants who did not tolerate 12 mg could stay on 4 mg, 6 mg, or 9 mg. The placebo group had a sham schedule with volume changes every 4 weeks, so that nobody knew who got the drug.

Two points follow from these tables. First, the trials do not agree on a single ladder. The obesity trial jumped from 4 mg to 8 mg, and the kidney trial record adds 6 mg and 9 mg steps. The phase 3 TRIUMPH records on ClinicalTrials.gov list their arms only as dose 1, 2, and 3. Second, the kidney trial record let a person stay at a lower step. A chart that shows one fixed march to 12 mg leaves out that detail.

Why online retatrutide charts disagree

When you compare the charts that rank for this search, you find several problems.

  • Invented steps. Some charts show 2, 4, 6, 8, 10, and 12 mg, or add 1 mg as a first step. Neither ladder matches the trial records above.
  • Missing source. Many charts give no trial number. Ask for the NCT number of any chart, then read the record on ClinicalTrials.gov.
  • Units with no concentration. A chart that says "20 units" is meaningless unless it also gives the mg per mL of the vial.
  • Trial results used as a promise. Weight loss in a trial came with medical checks, a pure study drug, and a fixed schedule. A product of unknown quality does not carry those results with it.

For more about the investigational status and what the trials track, see the retatrutide tracker guide.

Retatrutide units at 10 mg/mL: math with hypothetical numbers

People search for "retatrutide units at 10 mg/mL" because vials are often drawn with a U-100 insulin syringe, which is marked in units of volume. On a U-100 syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL.

The table below is math only. It uses hypothetical round mg amounts and hypothetical concentrations, so that the numbers are easy to check. No row is a dose, a step, or a recommendation, and no approved human dose of retatrutide exists. Confirm every draw with your prescriber or pharmacist before you inject.

Hypothetical mg amount mL at 10 mg/mL U-100 units at 10 mg/mL U-100 units at 5 mg/mL
1 mg 0.10 mL 10 units 20 units
2.5 mg 0.25 mL 25 units 50 units
5 mg 0.50 mL 50 units 100 units, a full 1 mL syringe
10 mg 1.00 mL 100 units, a full 1 mL syringe 200 units, more than one 1 mL syringe

The formula is: mL = mg amount ÷ concentration in mg per mL, and units = mL × 100. At 10 mg/mL, each unit holds 0.1 mg. At 5 mg/mL, each unit holds 0.05 mg. The same mg amount needs twice the units at half the concentration, which is how factor-of-two and factor-of-ten errors happen.

The FDA has reported hospital visits from this exact confusion with compounded semaglutide. Some patients drew 50 units when the instruction was 5 units. For the full concentration steps, see retatrutide dose in units, how to read an insulin syringe, and the free peptide calculator.

How Vital keeps the math next to the log

The hard part of any vial is to keep the right concentration with each entry. A note that says "40 units" means nothing six weeks later if you do not remember how the vial was mixed.

In Vital, you add a vial with the mg in the vial and the liquid in mL. The app shows the concentration, the U-100 units and mL to draw for the amount your prescriber or trial team gave you, and the number of doses per vial. It highlights a draw that is more than a 1 mL syringe holds. Each dose log keeps the unit you used, such as mg, mcg, units, or mL. You can set a reminder on set weekdays or every few days, and log the injection site.

Vital does not suggest a dose or a schedule. It records what your care team told you, so that you can show an exact history at your next visit. See dose log for a doctor visit and injection site rotation.

Warning signs that need care now

Retatrutide acts on three hormone receptors. The trials reported gastrointestinal effects and dose-related increases in heart rate. Get urgent care if you have:

  • Severe stomach pain that does not stop, with or without vomiting, which can be a sign of pancreatitis or a gallbladder problem.
  • Vomiting or diarrhea that stops you from keeping fluids down, or signs of dehydration such as dizziness and very little urine.
  • A racing or pounding heartbeat, chest pain, or fainting.
  • Swelling of the face, lips, or throat, or trouble breathing.
  • Shakiness, sweating, or confusion, mainly if you also take insulin or a sulfonylurea.

If you think you drew too much, call your prescriber or Poison Help at 1-800-222-1222. For dose increases on approved drugs, see side effects after a dose increase.


Retatrutide is an investigational drug of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Charts presented as an approved schedule

    Retatrutide has no FDA approval, no label, and no approved titration. Any chart is a copy of a trial design or an invention.

  • Steps that match no trial

    The phase 2 obesity trial record lists 2, 4, 8, and 12 mg steps, and a phase 2 kidney trial record lists 2, 4, 6, 9, and 12 mg. Ladders such as 2, 4, 6, 8, 10, 12 mg do not appear in these records.

  • Products labeled for research use

    The FDA has warned sellers of retatrutide labeled "for research purposes" or "not for human consumption." These products have no verified identity, purity, or strength.

  • Compounded retatrutide

    The FDA says retatrutide cannot be used in compounding under federal law.

  • Unit counts without a concentration

    A U-100 unit is 0.01 mL of liquid. The mg in each unit changes with the vial concentration, so a unit count alone can be wrong by a factor of two or more.

Frequently asked questions

  • No. Retatrutide is an investigational drug with no FDA approval, so no label, approved dose, or approved titration exists. Charts online copy a clinical trial design or invent one.

  • The phase 2 obesity trial tested 1, 4, 8, and 12 mg once weekly. The 12 mg arm started at 2 mg and went to 4 mg, 8 mg, and then 12 mg, according to the ClinicalTrials.gov record. These are trial facts, not a plan for anyone outside the trial.

  • The phase 2 obesity trial stepped from 2 mg to 4, 8, and 12 mg in its highest arm. A phase 2 kidney trial, NCT05936151, started at 2 mg weekly and stepped every 4 weeks to 4, 6, 9, and 12 mg. These are trial facts, not a plan for anyone outside a trial.

  • As math with hypothetical numbers: divide the mg by the vial concentration to get mL, then multiply by 100 for U-100 units. 5 mg at 10 mg/mL is 0.5 mL, or 50 units. No approved human dose exists. Confirm any draw with your prescriber or pharmacist.

  • No. The FDA says retatrutide cannot be used in compounding under federal law, and it has sent warning letters to companies that market it.

  • Not on November 20, 2026. Phase 3 TRIUMPH trials are listed on ClinicalTrials.gov, and some are completed, but trial results are not an approval. Check the FDA for the current status.

Sources

  1. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760) · ClinicalTrials.gov, U.S. National Library of Medicine
  2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial · PubMed, New England Journal of Medicine 2023
  3. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease (NCT05936151) · ClinicalTrials.gov, U.S. National Library of Medicine
  4. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1, NCT05929066) · ClinicalTrials.gov, U.S. National Library of Medicine
  5. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration
  6. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products · U.S. Food and Drug Administration

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.